Assessment of the effect of therapy in a rat model of glioblastoma using [18F]FDG and [18F]FCho PET compared to contrast-enhanced MRI.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 20 11 2020
accepted: 19 02 2021
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 12 10 2021
Statut: epublish

Résumé

We investigated the potential of [18F]fluorodeoxyglucose ([18F]FDG) and [18F]Fluoromethylcholine ([18F]FCho) PET, compared to contrast-enhanced MRI, for the early detection of treatment response in F98 glioblastoma (GB) rats. When GB was confirmed on T2- and contrast-enhanced T1-weighted MRI, animals were randomized into a treatment group (n = 5) receiving MRI-guided 3D conformal arc micro-irradiation (20 Gy) with concomitant temozolomide, and a sham group (n = 5). Effect of treatment was evaluated by MRI and [18F]FDG PET on day 2, 5, 9 and 12 post-treatment and [18F]FCho PET on day 1, 6, 8 and 13 post-treatment. The metabolic tumor volume (MTV) was calculated using a semi-automatic thresholding method and the average tracer uptake within the MTV was converted to a standard uptake value (SUV). To detect treatment response, we found that for [18F]FDG PET (SUVmean x MTV) is superior to MTV only. Using (SUVmean x MTV), [18F]FDG PET detects treatment effect starting as soon as day 5 post-therapy, comparable to contrast-enhanced MRI. Importantly, [18F]FDG PET at delayed time intervals (240 min p.i.) was able to detect the treatment effect earlier, starting at day 2 post-irradiation. No significant differences were found at any time point for both the MTV and (SUVmean x MTV) of [18F]FCho PET. Both MRI and particularly delayed [18F]FDG PET were able to detect early treatment responses in GB rats, whereas, in this study this was not possible using [18F]FCho PET. Further comparative studies should corroborate these results and should also include (different) amino acid PET tracers.

Identifiants

pubmed: 33667282
doi: 10.1371/journal.pone.0248193
pii: PONE-D-20-36019
pmc: PMC7935304
doi:

Substances chimiques

Contrast Media 0
fluoromethylcholine 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Choline N91BDP6H0X

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0248193

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Neurosurg Rev. 2018 Jan;41(1):67-76
pubmed: 27230829
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2188-93
pubmed: 20544193
Nucl Med Commun. 2017 Mar;38(3):242-249
pubmed: 27984537
J Nucl Med. 2002 Jan;43(1):92-6
pubmed: 11801711
Cancer Manag Res. 2014 Mar 24;6:149-70
pubmed: 24711712
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1446-1457
pubmed: 31865407
Int J Cancer. 2001 Jun 20;96(3):191-7
pubmed: 11410888
Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:16-21
pubmed: 16763817
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33
pubmed: 23053325
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Radiology. 2007 Aug;244(2):557-65
pubmed: 17581887
J Nucl Med. 2018 Nov;59(11):1672-1678
pubmed: 29626123
J Nucl Med. 2011 Jun;52(6):865-72
pubmed: 21571807
Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):319-23
pubmed: 12002705
J Neurooncol. 2009 Oct;95(1):87-93
pubmed: 19381442
Acta Neurochir (Wien). 2012 Feb;154(2):191-201; discussion 201
pubmed: 22130634
Neuroimage Clin. 2016 Dec 18;13:386-394
pubmed: 28116231
Eur Radiol. 2015 Oct;25(10):3017-24
pubmed: 25813014
J Neuroimaging. 2004 Jul;14(3):285-9
pubmed: 15228773
Semin Nucl Med. 2015 Mar;45(2):151-62
pubmed: 25704387
J Nucl Med. 2015 Mar;56(3):365-71
pubmed: 25678491
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Lancet Neurol. 2010 Sep;9(9):906-20
pubmed: 20705518
Cancer Immunol Immunother. 2009 Oct;58(10):1627-34
pubmed: 19221744
EJNMMI Res. 2017 Dec;7(1):25
pubmed: 28324340
J Neurooncol. 2010 Oct;100(1):17-29
pubmed: 20179990
Nucl Med Biol. 2006 Apr;33(3):287-94
pubmed: 16631076
Clin Nucl Med. 2011 Nov;36(11):978-81
pubmed: 21975383
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Front Neurol. 2016 Jul 28;7:120
pubmed: 27516754
Eur J Nucl Med. 2000 Jun;27(6):731-43
pubmed: 10901462
Clin Nucl Med. 2015 Jan;40(1):e40-5
pubmed: 25188640
J Neurosurg. 2019 Sep 1;131(3):657-666
pubmed: 31473668
Cancer Res. 2001 Jan 1;61(1):110-7
pubmed: 11196147
J Nucl Med. 2006 Feb;47(2):262-9
pubmed: 16455632
Semin Oncol. 2020 Apr - Jun;47(2-3):148-154
pubmed: 32513423
J Nucl Med. 2001 Dec;42(12):1805-14
pubmed: 11752077
Surgeon. 2014 Jun;12(3):148-57
pubmed: 24629841
PLoS One. 2016 Aug 25;11(8):e0161845
pubmed: 27559736
Cancers (Basel). 2019 Dec 07;11(12):
pubmed: 31817833
J Nucl Med. 2012 Jul;53(7):1048-57
pubmed: 22645298
Eur J Nucl Med. 2000 Jan;27(1):25-32
pubmed: 10654143
Nucl Med Biol. 2015 Jan;42(1):38-45
pubmed: 25218024
J Clin Oncol. 2017 Jul 20;35(21):2450-2456
pubmed: 28640704
Tumour Biol. 2014 Dec;35(12):12353-60
pubmed: 25182853
Br J Cancer. 2010 Aug 10;103(4):498-504
pubmed: 20628383
Ann Nucl Med. 2012 Jul;26(6):451-61
pubmed: 22566040
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Neurooncol. 2014 Nov;120(2):257-66
pubmed: 25069566
Clin Nucl Med. 2013 Jul;38(7):495-500
pubmed: 23640217
Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):317-24
pubmed: 14628097
J Clin Neurosci. 2008 May;15(5):545-51
pubmed: 18378459
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):294-301
pubmed: 15791438
Front Oncol. 2019 Aug 28;9:814
pubmed: 31555584
Curr Radiopharm. 2019;12(1):88-92
pubmed: 30117406
Hematol Oncol Clin North Am. 2012 Aug;26(4):825-53
pubmed: 22794286
J Nucl Med. 2004 Oct;45(10):1653-9
pubmed: 15471829
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Phys Med Biol. 2012 Mar 21;57(6):1675-84
pubmed: 22398239
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):176-84
pubmed: 20646863
Acta Oncol. 2004;43(4):396-403
pubmed: 15303502
Nucl Med Commun. 2012 Sep;33(9):954-9
pubmed: 22842224
J Korean Neurosurg Soc. 2014 Jan;55(1):5-11
pubmed: 24570811
Neurooncol Adv. 2019 May 28;1(1):vdz010
pubmed: 32642650
J Nucl Med. 2008 May;49(5):730-7
pubmed: 18413396
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):253-63
pubmed: 17926036
Clin Positron Imaging. 2000 Jul;3(4):147
pubmed: 11150750
Discov Med. 2012 Jul;14(74):13-20
pubmed: 22846199
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Am J Nucl Med Mol Imaging. 2014 Jun 07;4(4):365-84
pubmed: 24982822

Auteurs

Julie Bolcaen (J)

Radiation Biophysics Division, Department of Nuclear Medicine, National Research Foundation iThemba LABS, Faure, South Africa.

Benedicte Descamps (B)

Department of Electronics and Information Systems, IBiTech-MEDISIP, Ghent University, Ghent, Belgium.

Karel Deblaere (K)

Department of Radiology, Ghent University Hospital, Ghent, Belgium.

Filip De Vos (F)

Department of Radiopharmacy, Ghent University, Ghent, Belgium.

Tom Boterberg (T)

Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

Giorgio Hallaert (G)

Department of Neurosurgery, Ghent University Hospital, Ghent, Belgium.

Caroline Van den Broecke (C)

Department of Pathology, Ghent University Hospital, Ghent, Belgium.

Christian Vanhove (C)

Department of Electronics and Information Systems, IBiTech-MEDISIP, Ghent University, Ghent, Belgium.

Ingeborg Goethals (I)

Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH